Attention-deficit/hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment

Overview

Journal Curr Psychiatry Rep

Publisher Current Science

Specialty Psychiatry

Date 2012 Aug 14

PMID 22886581

Citations 18

Authors

Nikki Ivanchak

Kristen Fletcher

Gregory A Jicha

Affiliations

Soon will be listed here.

Abstract

Attentional deficits are frequently seen in isolation as the presenting sign and symptom of neurodegenerative disease, manifest as mild cognitive impairment (MCI). Persistent ADHD in the geriatric population could well be misconstrued as MCI, leading to the incorrect assumption that such persons are succumbing to a neurodegenerative disease process. Alternatively, the molecular, neuroanatomic, or neurochemical abnormalities seen in ADHD may contribute to the development of de novo late life neurodegenerative disease. The present review examines the issue of causality vs confound regarding the association of ADHD with MCI, suggesting that both are tenable hypotheses.

Citing Articles

Predictors of probable attention deficit hyperactivity disorder in elderly patients with mild cognitive impairment visiting a memory clinic.

Nagano S, Kamimura N, Sota S, Takahashi H, Suganuma N, Kazui H PCN Rep. 2024; 2(2):e104.

PMID: 38868147 PMC: 11114295. DOI: 10.1002/pcn5.104.

Motor Vehicle Crash Risk in Older Adult Drivers With Attention-Deficit/Hyperactivity Disorder.

Liu Y, Chihuri S, Mielenz T, Andrews H, Betz M, DiGuiseppi C JAMA Netw Open. 2023; 6(10):e2336960.

PMID: 37792374 PMC: 10551766. DOI: 10.1001/jamanetworkopen.2023.36960.

Risk of neurodegenerative disease or dementia in adults with attention-deficit/hyperactivity disorder: a systematic review.

Becker S, Chowdhury M, Tavilsup P, Seitz D, Callahan B Front Psychiatry. 2023; 14:1158546.

PMID: 37663597 PMC: 10469775. DOI: 10.3389/fpsyt.2023.1158546.

Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Dutta C, Christov-Moore L, Ombao H, Douglas P Front Hum Neurosci. 2022; 16:938501.

PMID: 36226261 PMC: 9548548. DOI: 10.3389/fnhum.2022.938501.

Identifying psychiatric and neurological comorbidities associated with hoarding disorder through network analysis.

Sordo Vieira L, Guastello A, Nguyen B, Nutley S, Ordway A, Simpson H J Psychiatr Res. 2022; 156:16-24.

PMID: 36219904 PMC: 9985179. DOI: 10.1016/j.jpsychires.2022.09.037.

References

Faraone S, Perlis R, Doyle A, Smoller J, Goralnick J, Holmgren M . Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57(11):1313-23. DOI: 10.1016/j.biopsych.2004.11.024. View

Dougherty D, Bonab A, Spencer T, Rauch S, Madras B, Fischman A . Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999; 354(9196):2132-3. DOI: 10.1016/S0140-6736(99)04030-1. View

Rocca W, Petersen R, Knopman D, Hebert L, Evans D, Hall K . Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011; 7(1):80-93. PMC: 3026476. DOI: 10.1016/j.jalz.2010.11.002. View

Biederman J, Spencer T . Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999; 46(9):1234-42. DOI: 10.1016/s0006-3223(99)00192-4. View

Naj A, Jun G, Beecham G, Wang L, Vardarajan B, Buros J . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5):436-41. PMC: 3090745. DOI: 10.1038/ng.801. View

Elia J, Vetter V . Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?. Paediatr Drugs. 2010; 12(3):165-75. DOI: 10.2165/11532570-000000000-00000. View

Biederman J . Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004; 65 Suppl 3:3-7. View

Doyle R, Frazier J, Spencer T, Geller D, Biederman J, Wilens T . Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006; 9(3):543-9. DOI: 10.1177/1087054705284091. View

Thapar A, Fowler T, Rice F, Scourfield J, van den Bree M, Thomas H . Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003; 160(11):1985-9. DOI: 10.1176/appi.ajp.160.11.1985. View

10.

Genro J, Kieling C, Rohde L, Hutz M . Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses. Expert Rev Neurother. 2010; 10(4):587-601. DOI: 10.1586/ern.10.17. View

11.

Banaschewski T, Becker K, Scherag S, Franke B, Coghill D . Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry. 2010; 19(3):237-57. PMC: 2839490. DOI: 10.1007/s00787-010-0090-z. View

12.

Niederhofer H . Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine. Med Hypotheses. 2011; 76(5):764-5. DOI: 10.1016/j.mehy.2011.02.011. View

13.

Spencer T, Biederman J, Madras B, Dougherty D, Bonab A, Livni E . Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry. 2007; 62(9):1059-61. PMC: 2715944. DOI: 10.1016/j.biopsych.2006.12.008. View

14.

Vaidya C, Bunge S, Dudukovic N, Zalecki C, Elliott G, Gabrieli J . Altered neural substrates of cognitive control in childhood ADHD: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2005; 162(9):1605-13. PMC: 4535914. DOI: 10.1176/appi.ajp.162.9.1605. View

15.

Watanabe M, Martin E, DeLeon O, Gaviria M, Pavel D, Trepashko D . Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci. 1995; 7(4):502-4. DOI: 10.1176/jnp.7.4.502. View

16.

Jicha G, Schmitt F, Abner E, Nelson P, Cooper G, Smith C . Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging. 2008; 31(10):1805-13. PMC: 2891418. DOI: 10.1016/j.neurobiolaging.2008.09.017. View

17.

Williams L, Tsang T, Clarke S, Kohn M . An 'integrative neuroscience' perspective on ADHD: linking cognition, emotion, brain and genetic measures with implications for clinical support. Expert Rev Neurother. 2010; 10(10):1607-21. DOI: 10.1586/ern.10.140. View

18.

Wilens T, Spencer T . Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010; 122(5):97-109. PMC: 3724232. DOI: 10.3810/pgm.2010.09.2206. View

19.

Padala P, Burke W, Shostrom V, Bhatia S, Wengel S, Potter J . Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010; 18(4):371-4. DOI: 10.1097/JGP.0b013e3181cabcf6. View

20.

Spencer T, Biederman J, Wilens T . Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am. 1999; 46(5):915-27, vii. DOI: 10.1016/s0031-3955(05)70163-2. View